CAL
BNGO icon

Capital Advisors Ltd’s Bionano Genomics BNGO Stock Holding History

Capital Advisors Ltd’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed – – 1392
2024
Q1 		$0 Buy
+1
New +$75 ﹤0.01% 1365
2022
Q4 		– Hold
0
– – – 1239
2022
Q3 		– Sell
-1
Closed -$1.32K – 1251
2022
Q2 		$0 Buy
+1
New +$1.03K ﹤0.01% 1019

Other funds holding BNGO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Capital Advisors Ltd's BNGO Position: Q2 2024 in Review

Capital Advisors Ltd sold out of Bionano Genomics (BNGO) in Q2 2024, closing a stake of 1 share.

Capital Advisors Ltd first reported a position in BNGO in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q1 2024. 53 funds tracked by Wall St. Rank hold BNGO as of Q2 2024.

  • Capital Advisors Ltd reported no remaining Bionano Genomics position as of Q2 2024 after selling out during the quarter.
  • Capital Advisors Ltd sold 1 Bionano Genomics share in Q2 2024.
  • Capital Advisors Ltd first reported a position in Bionano Genomics in Q2 2022 and held it in 2 quarters.
  • Capital Advisors Ltd's Bionano Genomics position peaked at $0 in Q1 2024.
  • 53 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2024.

Based on Capital Advisors Ltd's 13F filing for Q2 2024, filed 25 Jul 2024.